Important: Human evidence is limited to small pharmacodynamic studies. No large randomized controlled trials have established efficacy for anti-aging, body composition, or any indication in healthy adults.
Overview
Sermorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH) comprising the biologically active N-terminal 29 amino acids of the 44-residue native peptide. This truncated fragment retains full receptor-binding activity at the GHRH receptor (GHRHR) on pituitary somatotrophs while offering improved synthetic accessibility and a well-characterized pharmacokinetic profile.
Unlike exogenous growth hormone administration, sermorelin stimulates the pituitary to produce and secrete GH through its own endogenous feedback mechanisms. This axis-preserving mechanism maintains the pulsatile pattern of GH release, preserves hypothalamic-pituitary-axis (HPA) negative feedback, and avoids the supraphysiological GH levels associated with direct GH injection. Sermorelin was previously FDA-approved under the brand name Geref® for the diagnosis and treatment of growth hormone deficiency in children, providing a meaningful clinical safety dataset.
Mechanism of Action
Sermorelin binds to the GHRH receptor (GHRHR), a Gs-coupled GPCR expressed on anterior pituitary somatotroph cells. Receptor activation stimulates adenylyl cyclase, elevating intracellular cAMP and activating protein kinase A (PKA). PKA phosphorylates downstream targets that promote both GH synthesis (via CREB-mediated transcription of the GH gene) and GH secretion (via calcium-dependent exocytosis of GH-containing secretory granules).
Because sermorelin acts upstream of the pituitary, GH release remains subject to normal somatostatin-mediated inhibition and physiological negative feedback from circulating IGF-1. This preserves the pulsatile, amplitude-modulated pattern of GH secretion that characterizes normal physiology — a key mechanistic distinction from exogenous GH or longer-acting GHRH analogs like CJC-1295 DAC, which can blunt pulsatility through sustained receptor occupancy.
Research Evidence
- Previously FDA-approved (Geref®) for GH deficiency diagnosis and treatment in pediatric patients
- Stimulates pulsatile GH release while preserving somatostatin-mediated negative feedback
- Increases serum IGF-1 levels in GH-deficient subjects (Walker et al., 1990)
- Half-life of ~10–20 minutes allows precise dosing windows around sleep-onset GH pulse
- Axis-preserving mechanism avoids pituitary desensitization seen with continuous GHRH exposure
- Studied in adult GH deficiency, body composition, sleep quality, and anti-aging protocols
Bottom line: Sermorelin is one of the most established GHRH analogs in research, with a clinical history in pediatric GH deficiency and a well-characterized safety profile. Its axis-preserving mechanism and short half-life make it a distinct option compared to longer-acting analogs like CJC-1295 DAC or tesamorelin. All research-grade sermorelin from Purgo Labs is for laboratory use only.
Evidence & References
The full compound profile lists the evidence level, the studies behind each claim with PubMed links, and the adverse-effect record. Compound Review does not publish dosing protocols.
Sourcing & Quality
Sermorelin is available from Purgo Labs with third-party COA verification and research-grade purity standards. View Sermorelin at Purgo Labs.